Volume spike 24 Mar 2026: ZBH.SW Zimmer Biomet CHF67.50, earnings watch

A sharp intraday volume spike pushed ZBH.SW stock to CHF67.50 on SIX on 24 Mar 2026, down 4.26% from the previous close. Volume of 110.00 shares versus an average of 3.00 shows a relVolume 36.67 surge that suggests forced selling or institutional flows. The move comes with an upcoming earnings date of 04 May 2026, making this a short-term catalyst-driven trade to monitor closely on the Switzerland exchange in CHF.

Intraday volume spike: ZBH.SW stock price action

ZBH.SW stock opened at CHF67.50 and traded flat intraday with day high and low at CHF67.50. The stock recorded a one-day change of -3.00 CHF or -4.26%, signalling a sharp sell-off on light but extremely concentrated trades.

Volume of 110.00 versus an average volume of 3.00 produced a relative volume of 36.67, the key reason we flagged this as a volume spike setup for short-term traders and analysts watching order flow on SIX in Switzerland.

Valuation snapshot and fundamentals for ZBH.SW stock

Zimmer Biomet (ZBH.SW) shows a trailing EPS of 2.77 and a PE of 24.37 on the current price of CHF67.50. Key ratios include P/S 2.04, P/B 1.33, and dividend yield about 1.13%, reflecting moderate valuation relative to peers in Medical – Devices.

Balance and cash metrics show book value per share CHF64.43 and free cash flow yield 9.41%. Net debt to EBITDA sits near 3.38, and interest coverage is 4.16, which flags leverage risk but healthy cash generation.

Meyka AI rates ZBH.SW with a score out of 100 and model forecasts

Meyka AI rates ZBH.SW with a score out of 100: 77.36, Grade B+, Suggestion: BUY. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, analyst signals, and forecast inputs.

Meyka AI’s forecast model projects monthly CHF59.16, quarterly CHF87.16, and yearly CHF58.07. These model outputs show scenario divergence: the quarterly path implies upside, while the yearly projection implies downside of -13.93% versus the current price. Forecasts are model-based projections and not guarantees.

Technical indicators and short-term trade signals for ZBH.SW stock

Momentum indicators are elevated: RSI 75.66 (overbought) and ADX 84.17 (strong trend). MACD histogram sits at 0.21, and Keltner Channel lower band is CHF67.90, close to the intraday price, indicating tight intraday range compression.

Price averages show the 50-day at CHF78.58 and 200-day at CHF87.90, both above the current price. Traders should treat the current dip as a high-conviction volume event, not a confirmed reversal, and wait for volume-confirmed follow-through.

Earnings, catalysts and sector context for ZBH.SW stock

Earnings scheduled for 04 May 2026 is the primary catalyst. There is no broad price-target consensus available, so the earnings print could reprice multiples quickly in either direction. Recent financial growth shows revenue growth 7.20% for FY2025 but net income contraction of -21.97%, a mixed signal ahead of results.

Healthcare sector performance has been weak YTD (-8.00%), so ZBH.SW will likely trade relative to larger med-tech peers. Monitor guidance, margin commentary, and regional procedure volumes at earnings as drivers for post-release moves.

Risks, opportunities and a volume-spike trading approach

Risk factors include elevated net debt metrics, margin pressure in recent reports, and a long inventory cycle (days inventory 311.18). Opportunity lies in strong free cash generation and a Graham number near CHF72.01, which supports a value case if earnings stabilize.

For intraday or short-term traders following the volume spike strategy: consider waiting for a follow-through candle with volume above 200.00% of average before entering. Set a stop-loss near CHF64.00 for long setups and a conservative upside target near CHF75.00; alternative analyst scenarios point to a medium-term target of CHF90.00 and downside risk to CHF55.00 if guidance weakens.

Final Thoughts

ZBH.SW stock exhibited a clear intraday volume spike on 24 Mar 2026, with price at CHF67.50 and a relative volume of 36.67, indicating concentrated selling or institutional rebalancing on SIX in Switzerland. Short-term traders should treat this as a catalyst event ahead of earnings on 04 May 2026, and await confirmation before adding risk. Meyka AI’s forecast model projects a yearly level at CHF58.07, implying a -13.93% downside versus today, while the quarterly projection at CHF87.16 implies upside potential. Our Meyka grade of 77.36 (B+, BUY) balances cash generation and sector comparatives against leverage and margin risk. Key takeaways: watch volume-backed continuation for short-term trades, treat earnings as the primary trigger, and size positions to reflect a possible range between CHF55.00 and CHF90.00 depending on results. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.